NeoProfen Injection Recall Issued Due to Visible Particulates

|

All currently available lots of NeoProfen (ibuprofen lysine) Injection have been recalled because they failed to meet visible particulate quality requirements, which could cause serious and potentially life-threatening health problems.

The NeoProfen injection recall was issued on Friday by Lundbeck, Inc., involving two lots of the drug. These are the only two lots currently available to prescribers, so the recall will result in a temporary drug shortage.

NeoProfen is an ibuprofen lysine injection that is approved to treat premature infants weighing between 1 pound 2 ounces and 3 pounds 5 ounces (500 grams to 1500 grams) who are no more than 32 weeks gestational age. The non-steroidal anti-inflammatory therapy is used to close clinical significant patent ductus arteriosus (PDA) when usual medical management, such as fluid restriction, diuretics and respiratory support, are ineffective.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

Although there have been no adverse events reported in association with the visible particulate matter in NeoProfen Injections, the manufacturing problems could obstruct blood vessels and induce pulmonary emboli or activate platelets and neutrophils to induce anaphylactic reactions. Other problems from particulate matter in NeoProfen Injection could include foreign body granulomas and local irrittation of blood vessels.

Lundbeck, Inc. indicates that they will continue to closely monitor for reports of adverse drug reactions and product complaints, as the use of injectable products with particulats can be very serious and potentially life-threatening.

Product complaints related to the NeoProfen recall should be reported to Lundbeck by calling (800) 455-1141, and by making a report with the FDA’s MedWatch Program at http://www.fda.gov/safety/medwatch/default.htm.


0 Comments


Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

Canadian researchers say receiving Depo-Provera injections for more than a year triples the risk of brain tumors compared to women who take birth control pills.
A U.S. District Judge has ordered women involved in Depo-Provera lawsuits to inform him of any third-party pre-settlement loans they take out, as predatory interest rates may force them to reject settlement offers.